Literature DB >> 11273729

Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion.

E Marais1, S Genade, B Huisamen, J G Strijdom, J A Moolman, A Lochner.   

Abstract

The role of p38 mitogen-activated protein kinase (MAPK) in ischaemic preconditioning remains controversial. Since most previous studies focussed on events only during sustained ischaemia, the aim of this study was to establish the activation pattern of p38 MAPK during a multicycle preconditioning protocol, sustained ischaemia as well as reperfusion and to correlate these events with functional recovery of the isolated perfused rat heart. Isolated perfused rat hearts were preconditioned by 3x5 min global ischaemia followed by 25 min global ischaemia and 30 min reperfusion. Non-preconditioned hearts were subjected to 25 min global ischaemia and 30 min reperfusion. Hearts were freeze-clamped and p38 MAPK activation in tissue lysates was assessed by standard Western blotting techniques, using a dual phospho-p38 MAPK antibody as well as a non-radioactive IP-kinase assay. The results showed that transient dual phosphorylation and activation of p38 MAPK occurs during a 3x5 min preconditioning protocol: the activation was maximal during the first episode, becoming progressively lower during the second and third episodes. p38 MAPK activation was significantly less during both sustained ischaemia and reperfusion in preconditioned hearts, when compared with non-preconditioned hearts. Attenuation of p38 MAPK activity during sustained ischaemia and reperfusion was associated with improved functional recovery. The effect of inhibition of p38 MAPK activation on cardioprotection was further evaluated in adult, isolated cardiomyocytes. Administration of SB 203580 (1-10 microM) before and during the preconditioning protocol, had no effect on cell morphology and viability after 2 h hypoxia, compared to untreated preconditioned cardiomyocytes. When administered to non-preconditioned cells before the onset of 2 h hypoxia, it caused a significant improvement in both morphology and viability. In summary, the results suggest that attenuation of the kinase activity during sustained ischaemia and reperfusion may be an essential element of the preconditioning process.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11273729     DOI: 10.1006/jmcc.2001.1347

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  19 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

2.  Bone morphogenic protein-7 contributes to cerebral ischemic preconditioning induced-ischemic tolerance by activating p38 mitogen-activated protein kinase signaling pathway.

Authors:  Junhong Guan; Han Li; Tao Lv; Duo Chen; Ye Yuan; Shengtao Qu
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

3.  MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition.

Authors:  Lei Xu; Cecelia C Yates; Pamela Lockyer; Liang Xie; Ariana Bevilacqua; Jun He; Cynthia Lander; Cam Patterson; Monte Willis
Journal:  J Mol Cell Cardiol       Date:  2014-10-01       Impact factor: 5.000

Review 4.  Role of p38 inhibition in cardiac ischemia/reperfusion injury.

Authors:  Sarawut Kumphune; Siriporn Chattipakorn; Nipon Chattipakorn
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

5.  Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo.

Authors:  Joshua J Martindale; Jason A Wall; Diana M Martinez-Longoria; Prafulla Aryal; Howard A Rockman; Yiru Guo; Roberto Bolli; Christopher C Glembotski
Journal:  J Biol Chem       Date:  2004-10-18       Impact factor: 5.157

Review 6.  The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure.

Authors:  Michael S Marber; Beth Rose; Yibin Wang
Journal:  J Mol Cell Cardiol       Date:  2010-11-06       Impact factor: 5.000

Review 7.  Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.

Authors:  Tána Ravingerová; Miroslav Barancík; Monika Strnisková
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

8.  Anisomycin protects cortical neurons from prolonged hypoxia with differential regulation of p38 and ERK.

Authors:  Soon-Sun Hong; Hong Qian; Peng Zhao; Alia Bazzy-Asaad; Ying Xia
Journal:  Brain Res       Date:  2007-03-01       Impact factor: 3.252

9.  Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion.

Authors:  Britt N Fuglesteg; Naushaad Suleman; Crina Tiron; Tambuzai Kanhema; Lydia Lacerda; Thomas V Andreasen; Michael N Sack; Anne K Jonassen; Ole D Mjøs; Lionel H Opie; Sandrine Lecour
Journal:  Basic Res Cardiol       Date:  2008-05-23       Impact factor: 17.165

10.  Mitogen-activated protein kinases in the acute diabetic myocardium.

Authors:  Monika Strniskova; Miroslav Barancik; Jan Neckar; Tanya Ravingerova
Journal:  Mol Cell Biochem       Date:  2003-07       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.